Opinion|Videos|February 27, 2026
How Nurse Practitioners Aid in Treatment Selection and Communication in EGFR+ NSCLC
Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss how nurse practitioners add valuable insight to treatment selection in EGFR-mutated NSCLC.
Advertisement
Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss the integral role nurse practitioners play in treatment planning for patients with EGFR-mutated non–small cell lung cancer. Florez explains how advanced practice providers contribute clinical insight into patient comorbidities, preferences, and functional status when selecting therapy. McDonald describes how ongoing patient interaction enables early identification of concerns that may influence treatment decisions and adherence.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, being evaluated in pancreatic ductal adenocarcinoma.
ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.
PLN-101095 earned an FDA fast track designation in combination with pembrolizumab for solid tumors resistant to immune checkpoint inhibitors.
Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.
Harold P. Freeman, MD, pioneer of patient navigation and cancer disparities research, has died at 93. He spent decades bridging gaps in cancer care access.
Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.
Dana M. Chase, MD, and Angeles Alvarez Secord, MD, MHSc, discuss mocertatug rezetecan in gynecologic malignancies.
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
Updated SERENA-6 Data Sharpen the Debate on Early ctDNA-Guided Switching in Advanced Breast Cancer
3
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
4
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
5